Back to Search Start Over

Next-Generation Probiotics for Inflammatory Bowel Disease

Authors :
Marcella Pesce
Luisa Seguella
Alessandro Del Re
Jie Lu
Irene Palenca
Chiara Corpetti
Sara Rurgo
Walter Sanseverino
Giovanni Sarnelli
Giuseppe Esposito
Pesce, M
Seguella, L
Del Re, A
Lu, J
Palenca, I
Corpetti, C
Rurgo, S
Sanseverino, W
Sarnelli, G
Esposito, G
Source :
International Journal of Molecular Sciences. 23:5466
Publication Year :
2022
Publisher :
MDPI AG, 2022.

Abstract

Engineered probiotics represent a cutting-edge therapy in intestinal inflammatory disease (IBD). Genetically modified bacteria have provided a new strategy to release therapeutically operative molecules in the intestine and have grown into promising new therapies for IBD. Current IBD treatments, such as corticosteroids and immunosuppressants, are associated with relevant side effects and a significant proportion of patients are dependent on these therapies, thus exposing them to the risk of relevant long-term side effects. Discovering new and effective therapeutic strategies is a worldwide goal in this research field and engineered probiotics could potentially provide a viable solution. This review aims at describing the proceeding of bacterial engineering and how genetically modified probiotics may represent a promising new biotechnological approach in IBD treatment.

Details

ISSN :
14220067
Volume :
23
Database :
OpenAIRE
Journal :
International Journal of Molecular Sciences
Accession number :
edsair.doi.dedup.....61f86e38893c40f11a959d6895ecd651
Full Text :
https://doi.org/10.3390/ijms23105466